Care 001: Multicenter randomized open label phase II trial of neoadjuvant trastuzumabemtansine (T-DM1) in combination with lapatinib and nab-paclitaxel compared with paclitaxel, trastuzumab and pertuzumab in HER 2 neu over-expressed breast cancer patients (TEAL study).

Tejal Amar Patel; Joe Ensor; Sarah Creamer; Angel Augusto Rodriguez; Polly Ann Niravath; Jorge German Darcourt; Virginia G. Kaklamani; Jane Lowe Meisel; Xiaoxian Li; John G. Kuhn; Roberto R Rosato; Anna Belcheva; Toniva Boone; Jenny Chee Ning Chang

doi:10.1200/jco.2018.36.15_suppl.581

Care 001: Multicenter randomized open label phase II trial of neoadjuvant trastuzumabemtansine (T-DM1) in combination with lapatinib and nab-paclitaxel compared with paclitaxel, trastuzumab and pertuzumab in HER 2 neu over-expressed breast cancer patients (TEAL study).

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.581 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 581-581 ◽

Cited By ~ 1

Author(s):

Tejal Amar Patel ◽

Joe Ensor ◽

Sarah Creamer ◽

Angel Augusto Rodriguez ◽

Polly Ann Niravath ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Trial ◽

Breast Cancer Patients ◽

Open Label ◽

Open Label Phase ◽

Her 2

Download Full-text

Abstract P6-17-26: Care 001: multi-center randomized open-label phase II trial of neoadjuvant trastuzumab emtansine (T-DM1) in combination with lapatinib and nab-paclitaxel compared with paclitaxel, trastuzumab and pertuzumab in HER2-neu over-expressed breast cancer patients (TEAL study)

10.1158/1538-7445.sabcs18-p6-17-26 ◽

2019 ◽

Author(s):

SL Creamer ◽

TA Patel ◽

JE Ensor ◽

AA Rodriguez ◽

PA Niravath ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Trial ◽

Trastuzumab Emtansine ◽

Breast Cancer Patients ◽

Open Label ◽

Open Label Phase

Download Full-text

Bi-weekly docetaxel and gemcitabine regimen in her-2-negative and anthracycline-pretreated metastatic breast cancer patients: a multicenter phase II trial

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-011-1570-7 ◽

2011 ◽

Vol 68 (4) ◽

pp. 1009-1016 ◽

Cited By ~ 2

Author(s):

R. Murialdo ◽

F. Bertolotti ◽

G. Pastorino ◽

M. Mencoboni ◽

M. Bergaglio ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

Weekly Docetaxel ◽

Multicenter Phase ◽

Her 2

Download Full-text

Phase II Trial of Primary Systemic Therapy (PST) with Docetaxel (D) Followed by High-Dose Epirubicin in Combination with Cyclophosphamide (EC) Plus Concurrent Trastuzumab (T) For Stage II-III HER-2 Positive Breast Cancer Patients (PTS)

Annals of Oncology ◽

10.1016/s0923-7534(20)32973-2 ◽

2012 ◽

Vol 23 ◽

pp. ix142

Author(s):

P. Vici ◽

L. Pizzuti ◽

M. Mottolese ◽

D. Sergi ◽

A. Di Benedetto ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Systemic Therapy ◽

Phase Ii Trial ◽

High Dose ◽

Breast Cancer Patients ◽

Primary Systemic Therapy ◽

Her 2 ◽

Positive Breast Cancer

Download Full-text

Abstract LB-414: Comparison ofin vitroandin vivoimmunologic responses in a prospective, randomized, single-blinded phase II trial evaluating the HER-2/neupeptide vaccines GP2 and AE37 in breast cancer patients

10.1158/1538-7445.am2011-lb-414 ◽

2011 ◽

Author(s):

Alan K. Sears ◽

Guy T. Clifton ◽

Mark G. Carmichael ◽

David C. Van Echo ◽

Jarrod P. Holmes ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Trial ◽

Breast Cancer Patients ◽

Her 2

Download Full-text

The relationship between immunologic response and recurrence in a phase II trial evaluating the HER-2/neu peptide vaccines AE37 and GP2 in breast cancer patients in the adjuvant setting

Journal of the American College of Surgeons ◽

10.1016/j.jamcollsurg.2011.06.335 ◽

2011 ◽

Vol 213 (3) ◽

pp. S138

Author(s):

Alan K. Sears ◽

Guy T. Clifton ◽

Linda C. Benavides ◽

Jeremy D. Gates ◽

Jarrod P. Holmes ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Trial ◽

Immunologic Response ◽

Peptide Vaccines ◽

Breast Cancer Patients ◽

Adjuvant Setting ◽

Her 2 ◽

The Relationship

Download Full-text

Phase II Study of HER-2/neu Intracellular Domain Peptide-Based Vaccine Administered to Stage IV HER2 Positive Breast Cancer Patients Receiving Trastuzumab

10.21236/ada471552 ◽

2007 ◽

Author(s):

Mary L. Disis

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Stage Iv ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Her 2 ◽

Domain Peptide ◽

Positive Breast Cancer

Download Full-text

Phase II Study of a HER-2/neu Intracellular Domain Peptide-Based Vaccine Administered to Stage IV HER2 Positive Breast Cancer Patients Receiving Trastuzumab

10.21236/ada533841 ◽

2010 ◽

Author(s):

Mary L. Disis

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Stage Iv ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Her 2 ◽

Domain Peptide ◽

Positive Breast Cancer

Download Full-text

Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial

British Journal of Cancer ◽

10.1038/sj.bjc.6603351 ◽

2006 ◽

Vol 95 (7) ◽

pp. 788-793 ◽

Cited By ~ 43

Author(s):

A Chan ◽

◽

M Martin ◽

M Untch ◽

M G Gil ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Cancer Patients ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Her 2

Download Full-text

The effect of aspirin on circulating tumor cells in metastatic colorectal and breast cancer patients: a phase II trial study

Clinical & Translational Oncology ◽

10.1007/s12094-017-1806-z ◽

2017 ◽

Vol 20 (7) ◽

pp. 912-921 ◽

Cited By ~ 10

Author(s):

L. Yang ◽

Z. Lv ◽

W. Xia ◽

W. Zhang ◽

Y. Xin ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Phase Ii ◽

Phase Ii Trial ◽

Breast Cancer Patients

Download Full-text

Three-Year Follow-Up of Survival and Progression in a Phase II Trial of Gemcitabine Plus Carboplatin (Plus Trastuzumab in HER2+ Patients) in Metastatic Breast Cancer Patients.

10.1158/0008-5472.sabcs-09-2105 ◽

2009 ◽

Author(s):

D. Loesch ◽

L. Asmar ◽

K. McIntyre ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Breast Cancer Patients

Download Full-text